Page last updated: 2024-08-21

isoxazoles and Cruveilhier-Baumgarten Syndrome

isoxazoles has been researched along with Cruveilhier-Baumgarten Syndrome in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alawad, AS; Levy, C	1
Burnet, M; Deuschle, U; Garnys, L; Hambruch, E; Hayden, H; Kremoser, C; Mitteregger, D; Oberhuber, G; Peck-Radosavljevic, M; Podesser, BK; Reiberger, T; Riedl, F; Rohr-Udilova, N; Schubert, TL; Schwabl, P; Seeland, BA; Starlinger, P; Strobel, B; Trauner, M; Wagner, M	1
Cima, K; Desole, S; Graziadei, I; Kähler, CM; Vogel, W; Vogelsinger, H	1

Reviews

1 review(s) available for isoxazoles and Cruveilhier-Baumgarten Syndrome

Article	Year
FXR Agonists: From Bench to Bedside, a Guide for Clinicians. Digestive diseases and sciences, 2016, Volume: 61, Issue:12 Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid	2016

Article

Year

FXR Agonists: From Bench to Bedside, a Guide for Clinicians.

Digestive diseases and sciences, 2016, Volume: 61, Issue:12

Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid

2016

Other Studies

2 other study(ies) available for isoxazoles and Cruveilhier-Baumgarten Syndrome

Article	Year
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. Journal of hepatology, 2017, Volume: 66, Issue:4 Topics: Animals; Benzoates; Bile Acids and Salts; Bilirubin; Capillaries; Cholesterol; Disease Models, Animal; Hypertension, Portal; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Vascular Remodeling; Vascular Resistance	2017
Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan. Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:7-8 Topics: Endothelin Receptor Antagonists; Humans; Hypertension, Portal; Hypertension, Pulmonary; Isoxazoles; Male; Pilot Projects; Syndrome; Thiophenes; Treatment Outcome; Young Adult	2011

Article

Year

The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

Journal of hepatology, 2017, Volume: 66, Issue:4

Topics: Animals; Benzoates; Bile Acids and Salts; Bilirubin; Capillaries; Cholesterol; Disease Models, Animal; Hypertension, Portal; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Vascular Remodeling; Vascular Resistance

2017

Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.

Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:7-8

Topics: Endothelin Receptor Antagonists; Humans; Hypertension, Portal; Hypertension, Pulmonary; Isoxazoles; Male; Pilot Projects; Syndrome; Thiophenes; Treatment Outcome; Young Adult

2011